Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Laurence, Booth"'
Publikováno v:
European Medical Journal, Pp 127-133 (2022)
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer. More recently
Externí odkaz:
https://doaj.org/article/cdacbc83be84411aa1963794eeb48ed3
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib to enhance tumor cell killing. GZ17-6.02 int
Externí odkaz:
https://doaj.org/article/3573b92758b84eecb29e3a3dfd3deca6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells. Axitinib and HDAC inhibitors interacted in a greater than additive fashion to inac
Externí odkaz:
https://doaj.org/article/5ff1f49d5e3c41198e86b3f06d7ce526
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-
Externí odkaz:
https://doaj.org/article/837468e93d0e46f1a9917b694f144e3f
Publikováno v:
European Medical Journal Oncology, Vol 7, Iss 1, Pp 81-89 (2019)
It has been stated that developing a drug that can attack mutated RAS proteins is ‘the Holy Grail’ of cancer therapeutics. Through a series of unexpected findings, the authors discovered that the irreversible epidermal growth factor receptor 1/2/
Externí odkaz:
https://doaj.org/article/b4ba450397304f08ba11f3c47539ee3b
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We defined the lethal interaction between the novel therapeutic GZ17-6.02 and the standard of care combination of the MEK1/2 inhibitor trametinib and the B-RAF inhibitor dabrafenib in PDX isolates of cutaneous melanoma expressing a mutant B-RAF V600E
Externí odkaz:
https://doaj.org/article/6aa3d464e9f1493298d91bd326a49302
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/d050e1aeeb2f47a9bb8acc2cd1c8d522
Publikováno v:
Anti-Cancer Drugs. 34:544-550
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048ba93e5f1976afffbf3e6f47ef3251
https://doi.org/10.1097/cad.0000000000001425
https://doi.org/10.1097/cad.0000000000001425
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate A
Externí odkaz:
https://doaj.org/article/b87b8c46f31548329f746ae9e97f01dc
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/d9e04d01b2ed4c839ca8f0cf7278e1af